铂类化疗与PARP抑制剂用于生殖系BRCA致病性变异晚期乳腺癌患者(LATER-BC):进展后治疗的回顾性多中心分析
这项回顾性多中心研究纳入67例生殖系BRCA致病性变异晚期乳腺癌患者,分析铂类化疗(PBC)与PARP抑制剂(PARPi)序贯使用的获益。结果提示两者敏感与耐药部分重叠,既往PBC进展后PARPi仍显示活性。
要点
- 晚期一线前接受过(新)辅助PBC后使用PARPi者,PARPi中位无进展生存期6.1个月、疾病控制率67%。
- 晚期PBC后使用PARPi者,PARPi中位无进展生存期3.4个月、疾病控制率64%。
- 晚期PARPi后使用PBC者,PBC中位无进展生存期1.8个月、疾病控制率14%。
核心结论
- 在gBRCA-PV晚期乳腺癌患者中,对PARPi和PBC的敏感与耐药部分重叠。
- 既往PBC进展的患者中仍观察到PARPi活性。
研究设计与样本
- 回顾性多中心研究,共纳入来自六家中心的67例gBRCA-PV晚期乳腺癌患者。
- 第1组为接受(新)辅助PBC后在晚期使用PARPi者(N=12);第2组为晚期PBC后使用PARPi者(N=36);第3组为晚期PARPi后使用PBC者(N=21)。
- 报告各组中位无进展生存期(mPFS)和疾病控制率(DCR)。
主要发现
- 第1组PARPi-mPFS为6.1个月,PARPi-DCR为67%。
- 第2组PARPi-mPFS为3.4个月,PARPi-DCR为64%。
- 年龄<65岁和无铂间期(PFI)>6个月与更长的PARPi-PFS相关;既往PBC-PFS>6个月和PBC用于一线至二线与更长的PARPi-DCR相关。
- 第3组PBC-mPFS为1.8个月,PBC-DCR为14%。
- PARPi-PFS≥9个月和PARPi-FI≥6个月与更好的PBC-DCR相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with breast cancer (BC) harbouring a germinal BRCA pathogenic variant (gBRCA-PV) may have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP inhibitors (PARPi). As reported in ovarian cancer, however, sensitivity and resistance to these treatments could partially overlap. In patients with a gBRCA-PV and advanced BC (aBC), it remains unclear whether prior exposure to PARPi/PBC affects tumour response to subsequent PBC/PARPi, respectively. METHODS: We conducted a retrospective, multicentric study to investigate the clinical benefit of post-PBC PARPi and vice versa in patients with a gBRCA-PV and aBC. Patients included had received (neo)adjuvant PBC and then PARPi in advanced setting (group 1), PBC followed by PARPi (group 2) or PARPi followed by PBC (group 3), both in advanced setting. We reported median progression-free survival (mPFS) and disease control rate (DCR) in each group. RESULTS: A total of 67 patients from six centres were included. PARPi-mPFS in advanced setting was 6.1 months in patients in group 1 (N = 12), while PARPi-DCR was 67%. In group 2 (N = 36), PARPi-mPFS was 3.4 months and PARPi-DCR was 64%. Age < 65 years and platinum-free interval (PFI) > 6 months were associated with longer PARPi-PFS; previous PBC-PFS > 6 months and PBC in first to second line were associated with longer PARPi-DCR. Patients in group 3 (N = 21) reported a PBC-mPFS of 1.8 months and a PBC-DCR of 14%. PARPi-PFS ≥ 9 months and PARPi-FI ≥ 6 months were associated with better PBC-DCR. CONCLUSIONS: Sensitivity and resistance to PARPi and PBC partially overlap in patients with a gBRCA-PV and aBC. Evidence of PARPi activity emerged in patients who progressed on previous PBC.
引用
- Valenza C, Trapani D, Gandini S, et al. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. Eur J Cancer. 2023. PMID: 37437366. doi:10.1016/j.ejca.2023.112944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。